Comparative Effectiveness of Tirzepatide vs Thiazolidinedione in MASLD

9,262 matched patients per treatment arm from a retrospective cohort study using the TriNetX network. The research compares clinical outcomes for adults with MASLD treated with tirzepatide versus thiazolidinediones. The dataset, authored by Jheng-Yan Wu and last updated in May 2026, reports hazard ratios for mortality and adverse events.

Use Cases

• Comparing real-world drug effectiveness based on composite outcome measures described in the study
• Analyzing hazard ratios for major adverse events in MASLD patients based on reported clinical endpoints
• Conducting propensity score-matched cohort study methodology replication based on the described design

Strengths

• Large matched cohort of 9,262 patients per treatment arm
• Study reports specific hazard ratios with 95% confidence intervals for multiple clinical outcomes
• Data sourced from the multi-institutional TriNetX global health research network

Limitations

• Dataset is a 63.7 KB DOCX document, suggesting limited raw data scope
• Column-level documentation is absent; field semantics must be inferred after download
• Observational design precludes causal inference as noted in the conclusion

Provenance

Source

TriNetX global health research network

Collection Method

Retrospective, multi-institutional cohort study using propensity score matching

Freshness

Last updated 2026-05-15 05:41:13